TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 3295315

Group type: EXPERIMENTAL
Intervention: colestipol-niacin therapy
Number of subjects: 162
Study: 2695381

Group type: EXPERIMENTAL
Intervention: Diltiazem 120 mg t.i.d.
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 31064203

Group type: EXPERIMENTAL
Intervention: Coping Long Term with Active Suicide Program (CLASP‐A)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Enhanced Treatment as Usual (ETAU)
Number of subjects: 50
Study: 28214370

Group type: EXPERIMENTAL
Intervention: Tramadol (50 mg)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo (1 mL normal saline)
Number of subjects: 42
Study: 26204114

Group type: EXPERIMENTAL
Intervention: Quarterly feedback reporting
Number of subjects: 2167

Group type: COMPARATOR
Intervention: Control group (no feedback reporting)
Number of subjects: 2167

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 2167
Study: 22517566

Group type: EXPERIMENTAL
Intervention: multivessel percutaneous coronary intervention (mv‐PCI)
Number of subjects: 585

Group type: COMPARATOR
Intervention: coronary artery bypass graft surgery (CABG)
Number of subjects: 585
Study: 21823383

Group type: EXPERIMENTAL
Intervention: Ondansetron (0.1 mg/kg for children < 40 kg, 4 mg for children > 40 kg)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo (normal saline 2 ml)
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Ondansetron
Number of subjects: 70

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70

Group type: EXPERIMENTAL
Intervention: Agitated patients
Number of subjects: 70
Study: 19145638

Group type: EXPERIMENTAL
Intervention: Chinese medicinal herb complex (CCMH; a mixture of citronellol and extracts of G. lucidum, C. pilosula and A. sinensis)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Chinese medicinal herb complex (CCMH)
Number of subjects: 105
Study: 17306441

Group type: EXPERIMENTAL
Intervention: Docetaxel+prednisolone (30 mg m(‐2) weekly during 5 of 6 wk + prednisolone 5 mg x 2 per os daily)
Number of subjects: 109

Group type: COMPARATOR
Intervention: Prednisolone (5 mg x 2 per os daily)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: Docetaxel+prednisolone
Number of subjects: 109
Study: 15082979

Group type: EXPERIMENTAL
Intervention: Methylprednisolone (steroid)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Normal saline (placebo)
Number of subjects: 120
Study: 11440265

Group type: EXPERIMENTAL
Intervention: Clinical exam for equinus contracture defined as < or =5 degrees of ankle dorsiflexion
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Clinical exam for equinus contracture defined as < or =10 degrees of ankle dorsiflexion
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Clinical exam for no equinus defined as < or =5 degrees of ankle dorsiflexion
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Clinical exam for no equinus defined as < or =10 degrees of ankle dorsiflexion
Number of subjects: 68
Study: 9824787

Group type: EXPERIMENTAL
Intervention: Tiagabine 4 mg twice daily
Number of subjects: 13

Group type: COMPARATOR
Intervention: Tiagabine 4 mg twice daily with Erythromycin 500 mg twice daily
Number of subjects: 13

Group type: COMPARATOR
Intervention: Erythromycin 500 mg twice daily
Number of subjects: 13
Study: 7820516

Group type: EXPERIMENTAL
Intervention: Saphenous vein patch angioplasty
Number of subjects: 200

Group type: COMPARATOR
Intervention: Division-endarterectomy-anastomosis
Number of subjects: 200
Study: 3262028

Group type: EXPERIMENTAL
Intervention: A-calcitonin-gene-related peptide (10(-11) mol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: B-calcitonin-gene-related peptide (10(-11) mol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: A-calcitonin-gene-related peptide (10(-13) mol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: B-calcitonin-gene-related peptide (10(-13) mol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: A-calcitonin-gene-related peptide (10(-15) mol)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: B-calcitonin-gene-related peptide (10(-15) mol)
Number of subjects: 0
Study: 31563372

Group type: EXPERIMENTAL
Intervention: Foam Rolling (FR) for 60 seconds
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Foam Rolling (FR) for 120 seconds
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Rolling Massage (RM) for 60 seconds
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: Rolling Massage (RM) for 120 seconds
Number of subjects: 25
Study: 26481198

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation (60,000 IU/week for 6 weeks, then 60,000 IU/month for 3 months)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 150
Study: 26200237

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention
Number of subjects: 2898

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 2898

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2898
Study: 23549954

Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate (0.8 ± 0.1 mg/kg per day for 3 days; cycles per year 2.0 ± 0.1; duration 7.3 ± 1.1 years; n = 5)
Number of subjects: 9

Group type: COMPARATOR
Intervention: No treatment (n = 4)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Intravenous pamidronate
Number of subjects: 9

Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 9
Study: 22052309

Group type: EXPERIMENTAL
Intervention: NAFT-2
Number of subjects: 709

Group type: EXPERIMENTAL
Intervention: NAFT-1
Number of subjects: 709

Group type: COMPARATOR
Intervention: Vehicle 2 weeks
Number of subjects: 709

Group type: COMPARATOR
Intervention: Vehicle 4 weeks
Number of subjects: 709
Study: 19394939

Group type: EXPERIMENTAL
Intervention: n‐3 PUFA (2g/day) for 12 weeks
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 16968960

Group type: EXPERIMENTAL
Intervention: 20 mg of pantoprazole
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 40 mg of pantoprazole
Number of subjects: 0
Study: 15471756

Group type: EXPERIMENTAL
Intervention: Internet questionnaire (n=221)
Number of subjects: 442

Group type: COMPARATOR
Intervention: Mailed questionnaire (n=221)
Number of subjects: 442
Study: 11737514

Group type: EXPERIMENTAL
Intervention: Image analysis system for quantitative plaque measurement
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Image analysis system
Number of subjects: 15

Group type: COMPARATOR
Intervention: Turesky modification of the Quigley and Hein plaque index
Number of subjects: 15

Group type: COMPARATOR
Intervention: Addy plaque area index
Number of subjects: 15
Study: 9416720

Group type: EXPERIMENTAL
Intervention: M-6-G (Dosage A: 0.015 mg/kg bolus + 0.0072 mg x kg(‐1) x h(‐1) infusion)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: M-6-G (Dosage B: 0.029 mg/kg bolus + 0.014 mg x kg(‐1) x h(‐1) infusion)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: M-6-G (Dosage C: 0.044 mg/kg bolus + 0.022 mg x kg(‐1) x h(‐1) infusion)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Morphine (Dosage D: 0.14 mg/kg bolus + 0.05 mg x kg(‐1) x h(‐1) infusion)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: M-6-G combined with morphine (Dosage E: A + D)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo (Dosage F)
Number of subjects: 20
Study: 8237837

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 700

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 700
Study: 3307097

Group type: EXPERIMENTAL
Intervention: Kelfiprim (KP)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Co-trimoxazole (CO)
Number of subjects: 76
Study: 12095079

Group type: COMPARATOR
Intervention: 10 mg procyclidine
Number of subjects: 28

Group type: COMPARATOR
Intervention: 15 mg procyclidine
Number of subjects: 28
Study: 30343653

Group type: EXPERIMENTAL
Intervention: Mobile teledermoscopy (diagnosis using a phone camera)
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Results reviewed by a dermatologist
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Increased chance of detecting melanoma from 65-75% to 95%
Number of subjects: 113
Study: 27861362

Group type: EXPERIMENTAL
Intervention: Naloxone (3.25 mg/kg, 4 mg/mL)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 80
Study: 24760974

Group type: EXPERIMENTAL
Intervention: 30En%‐protein condition
Number of subjects: 58

Group type: COMPARATOR
Intervention: 5En%‐protein condition
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: 15En%‐protein condition
Number of subjects: 58
Study: 22284892

Group type: EXPERIMENTAL
Intervention: Bone marrow mononuclear cells (BMCs)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Expanded bone marrow cells enriched in CD90+ cells (TRCs)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both BMCs and TRCs
Number of subjects: 30
Study: 19660910

Group type: EXPERIMENTAL
Intervention: Chlorella supplementation (6.3g daily for 6 weeks)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo supplementation
Number of subjects: 52
Study: 19091084

Group type: EXPERIMENTAL
Intervention: Medical Outcomes Study Sleep Scale (MOS-Sleep)
Number of subjects: 396
Study: 16476256

Group type: EXPERIMENTAL
Intervention: PUVA baths (photosensitizer 8‐methoxypsoralen at a concentration of 2.6 mg/l)
Number of subjects: 167

Group type: COMPARATOR
Intervention: NBUVB radiation
Number of subjects: 167
Study: 12145014

Group type: COMPARATOR
Intervention: 12 mg lysine x kg(‐1) x d(‐1)
Number of subjects: 18

Group type: COMPARATOR
Intervention: 20 mg lysine x kg(‐1) x d(‐1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 28 mg lysine x kg(‐1) x d(‐1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: 36 mg lysine x kg(‐1) x d(‐1)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Overall conclusion
Number of subjects: 18
Study: 10548613

Group type: EXPERIMENTAL
Intervention: Carbon dioxide (CO(2)) uterine distension
Number of subjects: 30

Group type: COMPARATOR
Intervention: Normal saline (N/Saline) uterine distension
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Both CO(2) and N/Saline distension
Number of subjects: 30
Study: 7888365

Group type: EXPERIMENTAL
Intervention: Acyclovir 400 mg twice daily
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 2359062

Group type: EXPERIMENTAL
Intervention: Oral nifedipine
Number of subjects: 58

Group type: COMPARATOR
Intervention: Intravenous ritodrine hydrochloride
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Nifedipine
Number of subjects: 58
Study: 349689

Group type: EXPERIMENTAL
Intervention: Insadol (medicament group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 31121581

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Analysis System of Psychotherapy (CBASP)
Number of subjects: 268

Group type: COMPARATOR
Intervention: Supportive Psychotherapy (SP)
Number of subjects: 268
Study: 27296780

Group type: EXPERIMENTAL
Intervention: Ultrasound visual feedback treatment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Treatment without ultrasound visual feedback
Number of subjects: 12
Study: 27241116

Group type: EXPERIMENTAL
Intervention: Carbon nanoparticles
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 140
Study: 23889363

Group type: EXPERIMENTAL
Intervention: Placebo (sports performance drink)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Nocebo (fatigue-inducing drink)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Water
Number of subjects: 12
Study: 22190162

Group type: EXPERIMENTAL
Intervention: 10-minute recovery after heavy resistance exercise (5 deadlift repetitions at 85% 1RM)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control trial with no prior heavy resistance exercise (PHRE)
Number of subjects: 10
Study: 20124187

Group type: EXPERIMENTAL
Intervention: Lapatinib + Trastuzumab
Number of subjects: 296

Group type: COMPARATOR
Intervention: Lapatinib alone
Number of subjects: 296
Study: 18554393

Group type: EXPERIMENTAL
Intervention: Looking for Meaning intervention (12-session preventive intervention)
Number of subjects: 0

Group type: COMPARATOR
Intervention: 20-minute video movie (control condition)
Number of subjects: 0
Study: 16101614

Group type: EXPERIMENTAL
Intervention: Intervention booklet
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Appointment for postpartum visit
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: Information on maternal health
Number of subjects: 450

Group type: EXPERIMENTAL
Intervention: University education
Number of subjects: 450
Study: 12913401

Group type: EXPERIMENTAL
Intervention: Early eptifibatide administration (in the Emergency Department, n = 27)
Number of subjects: 55

Group type: COMPARATOR
Intervention: Late eptifibatide administration (12-24 h, n = 28)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Early eptifibatide administration
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: Both early and late eptifibatide administration
Number of subjects: 55
Study: 10077300

Group type: EXPERIMENTAL
Intervention: Standardized physical exercise for induction of general symptoms
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Equipment causing itching through skin irritation
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Physical exercise combined with equipment causing itching through skin irritation
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 64
Study: 7560365

Group type: EXPERIMENTAL
Intervention: Fluoride (F‐) concentrations in unstimulated saliva
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoride (F‐) concentrations in stimulated saliva
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fluoride (F‐) applications
Number of subjects: 0
Study: 1600595

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (400 mg/m2 given i.v. on day -7)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cyclophosphamide (timing varied: 5, 7, or 9 days before melphalan)
Number of subjects: 0
Study: 4065193

Group type: EXPERIMENTAL
Intervention: L-644,122 administered intravenously to healthy volunteers
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: L-644,122 administered by mouth to mild hypertensives
Number of subjects: 8

Group type: COMPARATOR
Intervention: Low dose intravenous L-644,122
Number of subjects: 8
Study: 31859706

Group type: EXPERIMENTAL
Intervention: MEL nanoparticles
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.12% chlorhexidine gluconate (CHX)
Number of subjects: 60
Study: 30290275

Group type: EXPERIMENTAL
Intervention: My Diabetes Profile (MDP) program
Number of subjects: 0

Group type: COMPARATOR
Intervention: Care as usual (Control)
Number of subjects: 0
Study: 26334188

Group type: EXPERIMENTAL
Intervention: Nebulized 3% hypertonic saline (HS)
Number of subjects: 68

Group type: COMPARATOR
Intervention: 0.9% normal saline (NS)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Both HS and NS
Number of subjects: 68
Study: 24836655

Group type: EXPERIMENTAL
Intervention: Arthroplasty
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Arthrodesis
Number of subjects: 260

Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 260
Study: 23828659

Group type: EXPERIMENTAL
Intervention: Updated probabilistic method
Number of subjects: 59

Group type: COMPARATOR
Intervention: Naranjo algorithm
Number of subjects: 59

Group type: COMPARATOR
Intervention: Liverpool algorithm
Number of subjects: 59

Group type: COMPARATOR
Intervention: Consensual expert judgement
Number of subjects: 59
Study: 21285287

Group type: EXPERIMENTAL
Intervention: Inspiratory muscle training
Number of subjects: 26
Study: 19247686

Group type: EXPERIMENTAL
Intervention: Exercise group (aerobic treadmill exercise in LBNP chamber + flywheel resistive training)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group (no exercise)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Exercise group
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study: 18179758

Group type: EXPERIMENTAL
Intervention: Hospital-supervised program of chest physical therapy (13 patients)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Control group (11 patients)
Number of subjects: 24
Study: 15131541

Group type: EXPERIMENTAL
Intervention: tenectaplase monotherapy
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: combination therapy with low-dose tenectaplase and eptifibatide
Number of subjects: 120
Study: 11177662

Group type: EXPERIMENTAL
Intervention: Intravascular beta-radiotherapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Prolonged antiplatelet therapy (6 months or more)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Broader radiation coverage of the intervention site
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gamma radiation
Number of subjects: 0
Study: 10048176

Group type: EXPERIMENTAL
Intervention: Ceftriaxone monotherapy (n = 135)
Number of subjects: 420

Group type: COMPARATOR
Intervention: Ceftriaxone in combination with other agents (n = 235)
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Ceftriaxone monotherapy
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Ceftriaxone treatment
Number of subjects: 420
Study: 8583094

Group type: EXPERIMENTAL
Intervention: Octreotide 100 micrograms bolus i.v. followed by 25 micrograms/h i.v. for 3 days
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Heater probe thermocoagulation (HPT)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Ranitidine 100 mg i.v. every 12 h
Number of subjects: 54
Study: 2147631

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg day-1
Number of subjects: 8

Group type: COMPARATOR
Intervention: Control conditions
Number of subjects: 8
Study: 7240557

Group type: EXPERIMENTAL
Intervention: Rise/decay time of at least 200 ms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rise/decay times shorter than 200 ms
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Very short rise/decay times
Number of subjects: 0
Study: 30932719

Group type: EXPERIMENTAL
Intervention: NKTR-181
Number of subjects: 1827

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1827
Study: 28402342

Group type: EXPERIMENTAL
Intervention: Flapless protocol
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Flap protocol
Number of subjects: 52

Group type: COMPARATOR
Intervention: Flapless and flap protocol
Number of subjects: 52
Study: 25576136

Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation (tDCS)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 33
Study: 23645227

Group type: EXPERIMENTAL
Intervention: Lutein/zeaxanthin, 10mg/2mg
Number of subjects: 4203

Group type: COMPARATOR
Intervention: No lutein/zeaxanthin (placebo)
Number of subjects: 4203
Study: 21450643

Group type: EXPERIMENTAL
Intervention: Inpatient cardiac rehabilitation (Rehab)
Number of subjects: 1474

Group type: COMPARATOR
Intervention: Usual care (Hosp)
Number of subjects: 1474
Study: 19969181

Group type: EXPERIMENTAL
Intervention: Indwelling microelectrode in the tibialis anterior
Number of subjects: 16

Group type: COMPARATOR
Intervention: Twitch interpolation technique without a microelectrode
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Visual feedback provided
Number of subjects: 16
Study: 18693804

Group type: EXPERIMENTAL
Intervention: Patients with 2 ADEs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Patients with 1 ADE
Number of subjects: 0

Group type: COMPARATOR
Intervention: Patients with no ADEs
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Single ADE
Number of subjects: 0
Study: 15234277

Group type: EXPERIMENTAL
Intervention: Cevimeline, 20 mg three times daily
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Cevimeline, 30 mg three times daily
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 11529977

Group type: EXPERIMENTAL
Intervention: Ad libitum feeding regimen
Number of subjects: 100

Group type: COMPARATOR
Intervention: Prescribed feeding regimen
Number of subjects: 100
Study: 9763788

Group type: EXPERIMENTAL
Intervention: Phase contrast gradient-echo after gadolinium injection
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: TurboSTIR
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: MISTEC-Chopper
Number of subjects: 10
Study: 8080512

Group type: EXPERIMENTAL
Intervention: High dose intensity (400 mg cyclophosphamide, 40 mg doxorubicin, 400 mg fluorouracil for six cycles)
Number of subjects: 1572

Group type: EXPERIMENTAL
Intervention: Moderate dose intensity (600 mg cyclophosphamide, 60 mg doxorubicin, 600 mg fluorouracil for four cycles)
Number of subjects: 1572

Group type: COMPARATOR
Intervention: Low dose intensity (half the total dose of the other two groups)
Number of subjects: 1572
Study: 2140372

Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 103

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 103
Study: 7433897

Group type: EXPERIMENTAL
Intervention: Carbenoxolone, 150 mg/daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cimetidine, 400 mg at bedtime
Number of subjects: 0
Study: 30367939

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (100,000 IU bolus followed by 4000 IU/d)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 54

Group type: EXPERIMENTAL
Intervention: Cholecalciferol supplementation (100,000 IU bolus followed by 4000 IU/d) in individuals with greater vitamin D deficiency (25(OH)D < 30 nmol/L)
Number of subjects: 54
Study: 28686982

Group type: EXPERIMENTAL
Intervention: Biofeedback with pelvic floor muscle exercise and lifestyle advice
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group receiving lifestyle advice and pelvic floor muscle exercise without biofeedback
Number of subjects: 40
Study: 25946376

Group type: EXPERIMENTAL
Intervention: Cumulative print plus telephone intervention at 12 months
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: Print intervention alone at 6 months
Number of subjects: 1280

Group type: COMPARATOR
Intervention: Cumulative interventions vs print intervention alone
Number of subjects: 1280

Group type: EXPERIMENTAL
Intervention: Effectiveness of intervention among ethnic subgroups
Number of subjects: 1280
Study: 24001701

Group type: EXPERIMENTAL
Intervention: Behavioral treatment
Number of subjects: 232

Group type: COMPARATOR
Intervention: Supportive therapy
Number of subjects: 232